LCM
HOWL icon

Lynx1 Capital Management’s Werewolf Therapeutics HOWL Stock Holding History

Lynx1 Capital Management’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$237K Hold
657,786
– – 0.03% 21
2026
Q1 		$548K Buy
657,786
+1,860
+0.3% +$1.27K 0.09% 18
2025
Q4 		$416K Buy
+655,926
New +$797K 0.08% 18

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Lynx1 Capital Management's HOWL Position: Q2 2026 in Review

Lynx1 Capital Management held its Werewolf Therapeutics (HOWL) position steady in Q2 2026 at 657,786 shares worth $237K. The position accounts for 0.03% of the portfolio, ranked #21.

Lynx1 Capital Management first reported a position in HOWL in Q4 2025 and has held it in 3 quarters since. The position peaked at $548K in Q1 2026. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • Lynx1 Capital Management held 657,786 shares of Werewolf Therapeutics worth $237K as of Q2 2026.
  • Lynx1 Capital Management left its Werewolf Therapeutics share count unchanged in Q2 2026.
  • Werewolf Therapeutics made up 0.03% of Lynx1 Capital Management's portfolio in Q2 2026, its #21 holding.
  • Lynx1 Capital Management first reported a position in Werewolf Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Lynx1 Capital Management's Werewolf Therapeutics position peaked at $548K in Q1 2026.
  • 45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on Lynx1 Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.